The potential usefulness of gain-of-function-based approaches in cancer research is further confirmed by recent evidence of the involvement of the PI3K pathway in the resistance of human breast cancer to the HER2-blocking antibody Trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.